Core Insights - The company reported a total revenue of 880 million yuan for 2024, representing a year-on-year increase of 10%, and a net profit attributable to shareholders of 250 million yuan, up 11% year-on-year [1] - In Q1 2025, the company achieved total revenue of 220 million yuan, with a year-on-year increase of 15% but a quarter-on-quarter decrease of 6%, and a net profit of 70 million yuan, reflecting a year-on-year increase of 16% and a quarter-on-quarter increase of 37% [1] Revenue and Market Performance - The company saw a continuous increase in market share, achieving record-high performance in 2024. The sales volume of nucleating agents reached 9,727.5 tons, up 32.0% year-on-year, generating revenue of 510 million yuan, a 24.0% increase year-on-year, with a gross margin of 55.91%, down 1.12 percentage points [2] - The sales volume of synthetic hydrotalcite was 7,037.4 tons, a 4.6% year-on-year increase, with revenue of 120 million yuan, down 1.0% year-on-year, and a gross margin of 47.02%, up 2.59 percentage points [2] - The sales volume of NDO composite additives reached 1,653.9 tons, up 16.9% year-on-year, with revenue of 60 million yuan, a 28.3% increase year-on-year, and a gross margin of 24.92%, down 1.30 percentage points [2] - The sales volume of antioxidants was 4,410.9 tons, up 15.3% year-on-year, generating revenue of 70 million yuan, down 20.2% year-on-year, with a gross margin of 14.93%, down 7.39 percentage points [2] - In Q1 2025, the company's gross margin improved significantly to 47.15%, with a year-on-year increase of 1.60 percentage points and a quarter-on-quarter increase of 7.89 percentage points, while the net margin was 32.46%, up 0.24 percentage points year-on-year and 10.07 percentage points quarter-on-quarter [2] Strategic Developments - The company is planning to acquire at least 51% of the shares of ITO target material leader Yingri Technology, which will facilitate resource sharing, brand enhancement, supply chain collaboration, cost optimization, and talent exchange, thereby enhancing core competitiveness and promoting high-quality development [3] - The completion and commissioning of the Nansha plant project at the end of 2024 significantly increased the company's production capacity, with optimized resource allocation further reducing costs and increasing efficiency [3] Investment Outlook - The demand for polymer material additives is expected to grow rapidly, with increasing self-sufficiency. The company forecasts net profits attributable to shareholders of 308 million yuan, 396 million yuan, and 478 million yuan for 2025-2027, corresponding to price-earnings ratios of 21.7, 16.9, and 14.0 times, respectively, maintaining a "buy" rating [3]

Core Insights - The company reported a revenue of 882 million RMB for 2024, representing a year-on-year growth of 10.31%, and a net profit attributable to shareholders of 250 million RMB, up 10.68% year-on-year [1][3] - In Q4 2024, the company achieved a revenue of 234 million RMB, with a year-on-year increase of 8.83%, but the net profit decreased by 10.51% to 52.34 million RMB [1] - For Q1 2025, the company generated a revenue of 220 million RMB, marking a 14.97% year-on-year growth, and a net profit of 71.46 million RMB, which is a 15.82% increase year-on-year [1] Financial Performance - The company has achieved record high profitability, with a continuous double-digit growth in performance for the tenth consecutive year [2][3] - The projected revenues for 2025-2027 are 1.138 billion RMB, 1.4 billion RMB, and 1.735 billion RMB respectively, with net profits of 283 million RMB, 337 million RMB, and 412 million RMB [5] Market Position and Strategy - The company is benefiting from the ongoing US-China trade disputes, with an increasing market share in high polymer material additives [3] - The company has over 180 different types of nucleating agents, synthetic hydrotalcite, and composite additives, enabling it to provide one-stop raw material supply to high-quality downstream customers [3] - The company is actively pursuing product innovation and expanding applications to enhance market share and steady growth [3] M&A Activity - The company signed an acquisition agreement to purchase at least 51% of a semiconductor materials company, with an estimated valuation of 1.8 billion RMB for the target company [4] - The target company specializes in high-performance sputtering targets, which are essential materials in the electronics manufacturing industry [4]

Investment Rating - The report maintains a "Strong Buy" investment rating for the company [2][5]. Core Views - The company has achieved record high quarterly profits, benefiting from domestic substitution amid the US-China trade dispute. In 2024, the company reported revenue of 882 million yuan, a year-on-year increase of 10.31%, and a net profit attributable to shareholders of 250 million yuan, up 10.68% [1][10]. - The company is actively pursuing mergers and acquisitions in the semiconductor materials sector to achieve synergistic development, with a planned acquisition of at least 51% of a target company valued at approximately 1.8 billion yuan [5][10]. Summary by Sections Company Profitability - The company has seen continuous improvement in profitability, with a market share increase and record high performance for ten consecutive years. The revenue for 2024 was 882 million yuan, with a net profit of 250 million yuan, both achieving historical highs [9][10]. - The company’s new production facility in Nansha has successfully commenced operations, significantly enhancing production capacity [12][13]. Core Products - The main products include nucleating agents, synthetic hydrotalcite, antioxidants, and composite additives, which are critical materials for achieving domestic production of high-performance resin materials [14][15]. Competitive Advantages - The company boasts a comprehensive product system and superior product performance, with over 300 different models of nucleating agents and other additives available for mass production [20]. - The company has strong R&D capabilities and continuous innovation, supported by a team of highly skilled professionals and partnerships with leading universities [21][22]. - The company has a robust patent portfolio, with 76 valid patents, including 59 invention patents, showcasing its commitment to technological advancement [23][24]. - The company adheres to green and efficient production processes, recognized as a "green factory" and a "zero-waste factory" [25]. - The company has established stable and reliable customer resources, including major energy and chemical companies, ensuring a strong market position [26]. Financial Data and Valuation - The company forecasts revenues of 1.138 billion yuan, 1.4 billion yuan, and 1.735 billion yuan for 2025, 2026, and 2027, respectively, with net profits projected at 283 million yuan, 337 million yuan, and 412 million yuan for the same years [6][36]. - The current price-to-earnings (PE) ratios are projected to be 22.9, 19.2, and 15.8 for 2025, 2026, and 2027, respectively [6][36].

Group 1 - The company achieved operating revenue of 882 million yuan in 2024, a year-on-year increase of 10.31%, and a net profit attributable to shareholders of 250 million yuan, up 10.68% year-on-year [1] - The sales net profit margin was 28.37%, an increase of 0.09 percentage points year-on-year, with the main product, nucleating agents, generating revenue of 511 million yuan, a growth of 24.09% [1] - The company’s nucleating agent sales volume reached 9,727.54 tons, a year-on-year increase of 32.03%, with a gross margin of 55.91%, down 1.12 percentage points [1] Group 2 - The company’s nucleating agent production capacity has doubled following the completion of its IPO fundraising projects, with a total capacity of 14,400 tons per year approved and operational since January 2024, and an additional 14,500 tons per year starting production testing in November 2024 [1] - The company plans to acquire at least 51% of Wuhu Yingri Technology Co., Ltd. for cash, with an estimated total valuation of 1.8 billion yuan, which will enhance its presence in the display materials sector [2] - The domestic nucleating agent import substitution rate is expected to accelerate due to the 125% tariff imposed on U.S. imports, with the company positioned to benefit from increased demand for domestic products [2]

Core Insights - The company reported a revenue of 882 million RMB for 2024, representing a year-on-year increase of 10%, and a net profit attributable to shareholders of 250 million RMB, up 11% year-on-year [1] - In Q1 2025, the company achieved a revenue of 220 million RMB, reflecting a 15% increase year-on-year, with a net profit of 71 million RMB, up 16% year-on-year [1] Revenue Breakdown - For FY 2024, the revenue from nucleating agents, synthetic hydrotalcite, NDO composite additives, and antioxidants was 510 million, 120 million, 60 million, and 70 million RMB respectively, with year-on-year changes of +24%, -1%, +28%, and -20% [2] - The gross profit margins for these products were 56%, 47%, 25%, and 15%, with year-on-year changes of -1, +3, -1, and -7 percentage points respectively [2] - The sales volume of nucleating agents reached 9,728 tons, marking a 32% increase year-on-year [2] Market Outlook - The national polypropylene production in 2024 is projected to be 34.72 million tons, a 7% increase year-on-year, with total capacity expected to reach 43.39 million tons, up 9% year-on-year [2] - The demand for nucleating agents is anticipated to grow due to the increasing application of polypropylene materials in emerging fields such as new energy and environmental protection [2] Strategic Acquisition - The company is planning to acquire at least 51% of YINGRI Technology, a leading manufacturer of ITO targets, with an estimated valuation of 1.8 billion RMB for 100% of the shares [3] - YINGRI Technology is recognized as a "national-level specialized and innovative small giant enterprise" and has achieved technical parity with foreign counterparts in large-size ITO target manufacturing [3] - The acquisition is expected to create synergies in customer resource sharing and brand influence, facilitating the company's entry into the display industry [3] Profit Forecast - The projected net profit attributable to shareholders for 2025-2027 is estimated to be 330 million, 440 million, and 540 million RMB respectively [4]

Group 1 - The core viewpoint of the articles highlights the strong financial performance and strategic growth initiatives of Chenghe Technology Co., Ltd, including revenue growth and a significant acquisition to enhance its market position [1][2][3] - In 2024, the company achieved an operating income of 882 million yuan, a year-on-year increase of 10.31%, and a net profit attributable to shareholders of 250 million yuan, up 10.68% [1] - For Q1 2025, the company reported an operating income of 220 million yuan, reflecting a year-on-year growth of 14.97%, and a net profit of 71 million yuan, which is a 15.82% increase, marking a historical high for quarterly earnings [1] Group 2 - Chenghe Technology is recognized as a national-level "specialized, refined, and innovative" small giant enterprise and a "green factory," focusing on the research and production of high-performance polymer materials and additives [1] - The company is pursuing strategic acquisitions to extend its industrial chain, including a planned acquisition of at least 51% of Wuhu Yingri Technology Co., Ltd, valued at 1.8 billion yuan, which will allow Chenghe to gain control over the display materials sector [2] - The acquisition of Yingri Technology, a leading player in high-performance sputtering targets, is expected to enhance Chenghe's capabilities in the display industry and open new growth opportunities through technological synergies [2] Group 3 - Looking ahead, Chenghe Technology aims to solidify its competitive edge through technological self-sufficiency and expand application scenarios via mergers and acquisitions, leveraging policy benefits for global expansion [3] - The company is transitioning from a single material supplier to a comprehensive solution provider for polymer materials, driven by domestic substitution and industry chain collaboration [3] - With breakthroughs in high-end fields such as display panels and semiconductors, along with ongoing international certifications, Chenghe Technology is poised to play a more significant role in the global high-end materials value chain [3]

呈和科技股份有限公司 2024 年度独立董事述职报告 呈和科技股份有限公司 2024 年度独立董事述职报告 本人是呈和科技股份有限公司（以下简称"公司"）独立董事，根据《中华人民共和国 公司法》（以下简称《公司法》）《中华人民共和国证券法》《上市公司独立董事管理办法》 《呈和科技股份有限公司章程》（以下简称《公司章程》）等法律法规、规章制度和文件的 规定与要求，认真、勤勉地履行独立董事职责，按时出席相关会议，认真审议董事会各项议 案，对公司重大事项发表独立意见，维护公司和全体股东的利益。现就本人 2024 年任职期间 履行独立董事职责的情况报告如下： 一、独立董事的基本情况 （一）报告期内个人履历、专业背景以及兼职情况 阙占文，1979 年生，中国国籍，无境外永久居留权，博士研究生学历。2016 年 12 月至 今任中山大学法学院副教授、博士生导师；2023 年 9 月至今，任公司独立董事。 （二）独立性情况说明 作为公司的独立董事，本人及直系亲属均不在公司或其附属企业担任除独董之外的其他 职务，也未在公司主要股东担任任何职务，与公司或公司控股股东无关联关系，具备《上市 公司独立董事管理办法》《公司章程》所要 ...

呈和科技股份有限公司 2024 年度独立董事述职报告 呈和科技股份有限公司 2024 年度独立董事述职报告 一、独立董事的基本情况 2024 年，呈和科技股份有限公司（以下简称"公司"）第三届董事会独立董事为叶罗沅 先生、燕学善先生、阙占文先生，任期自 2023 年 9 月 5 日至 2026 年 9 月 4 日。 （一）报告期内个人履历、专业背景以及兼职情况 叶罗沅先生，1981 年 3 月生，中国国籍，无境外永久居留权，会计学专业本科学历，具 有中国注册会计师、中国注册税务师、美国注册会计师资格。2004 年 7 月至 2008 年 9 月， 任普华永道中天会计师事务所（特殊普通合伙）广州分所高级审计师；2008 年 10 月至 2010 年 7 月，任麦楷博平（北京）财务咨询有限公司经理；2010 年 7 月至 2011 年 9 月，任广州 邦维财务咨询有限公司合伙人；2011 年 10 月至 2014 年 3 月，任香榕（天津）投资管理合伙 企业（有限合伙）投资总监；2014 年 3 月至今，任广东锦石私募证券投资管理有限公司监事、 合规负责人；2020 年 4 月至今，任公司独立董事；2022 年 ...

呈和科技股份有限公司 2024 年度独立董事述职报告 燕学善先生，1986 年 10 月生，中国国籍，无境外永久居留权，法律硕士专业，硕士研 究生学历，具有中国律师执业资格。2010 年 7 月至 2014 年 10 月，任北京市康达律师事务所 律师；2014 年 11 月至 2017 年 10 月，任北京大成（广州）律师事务所合伙人律师；2017 年 11 月至今，任北京市康达（广州）律师事务所高级合伙人律师；2020 年 4 月至今，任公司独 立董事；2023 年 12 月至今，任广东纽恩泰新能源科技股份有限公司独立董事。 （二）独立性情况说明 2024 年，呈和科技股份有限公司（以下简称公司）第三届董事会独立董事为叶罗沅先生、 燕学善先生、阙占文先生，任期自 2023 年 9 月 5 日至 2026 年 9 月 4 日。 呈和科技股份有限公司 2024 年度独立董事述职报告 一、独立董事的基本情况 （一）报告期内个人履历、专业背景以及兼职情况 （三）现场考察及工作情况 本人作为公司独立董事，独立、客观、审慎地对公司 2024 年度董事会所有议案行使表决 权。本着勤勉尽责的态度，在每次董事会前认真审阅议案 ...

呈和科技股份有限公司 2024 年度会计师事务所的履职情况评估报告 呈和科技股份有限公司 2024 年度会计师事务所的履职情况评估报告 呈和科技股份有限公司（以下简称"公司"）聘请立信会计师事务所（特殊普通合伙） （以下简称"立信"）作为公司 2024 年度出具审计报告的会计师事务所。 根据财政部、国务院国有资产监督管理委员会、中国证券监督管理委员会颁布的《国有 企业、上市公司选聘会计师事务所管理办法》，公司对立信在 2024 年度的审计工作的履职情 况进行了评估。具体情况如下： 呈和科技股份有限公司 2024 年度会计师事务所的履职情况评估报告 | 公司同行业上市 | 56 | | --- | --- | | 公司审计客户数 | | | 量 | | （二） 投资者保护能力 截至 2024 年 12 月 31 日，立信已累计计提职业风险基金人民币 1.66 亿元以上，购买的 职业保险累计赔偿限额超过人民币 10.50 亿元，职业风险基金计提及职业保险购买符合财政 部关于《会计师事务所职业风险基金管理办法》等文件的相关规定。立信近三年未因执业行 为在相关民事诉讼中被判定需承担民事责任。 （三） 诚信记录 立信近 ...